Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

@article{Martin2009SimplificationOA,
  title={Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.},
  author={Allison Martin and Mark Bloch and J Amin and David Baker and David A. Cooper and Sean Emery and Andrew Carr},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2009},
  volume={49 10},
  pages={1591-601}
}
BACKGROUND There are 2 once-daily, fixed-dose-combination, dual-nucleoside analogue tablets: tenofovir 300 mg-emtricitabine 200 mg (TDF-FTC) and abacavir 600 mg-lamivudine 300 mg (ABC-3TC). Which fixed-dose-combination tablet is more effective and safe is uncertain. METHODS We compared TDF-FTC and ABC-3TC in a randomized, open-label, 96-week trial in which either fixed-dose-combination was substituted for current nucleoside treatments in human leukocyte antigen-B*5701-negative adults with… CONTINUE READING
101 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 101 extracted citations

Similar Papers

Loading similar papers…